UNIVERSITY OF MINNESOTA

Trump's health agency picks, including Marty Makary for FDA, Dave Weldon for CDC, and Janette Nesheiwat for Surgeon General, raise concerns over potential changes to vaccines and treatments. Critics highlight their controversial views on vaccine safety and efficacy.

Trump's health agency nominees, including Marty Makary for FDA, Dave Weldon for CDC, and Janette Nesheiwat for Surgeon General, raise concerns due to their controversial views on vaccines. Robert F. Kennedy Jr., a prominent vaccine skeptic, is tapped to lead HHS, signaling potential major changes in public health policy.

Postmenopausal women aged 40-65 with moderate-to-severe hot flashes were recruited for a 12-week study in Washington, DC, comparing a low-fat vegan diet with usual diets. The vegan group consumed ½ cup of cooked soybeans daily, tracked hot flashes via a mobile app, and adhered to dietary records. Both groups received vitamin B12 supplements and maintained consistent physical activity. Statistical analysis used repeated measures ANOVA to assess changes in hot flashes, body weight, and dietary indices.

Rushford Council meeting on November 12 saw $15,000 from the Fire Relief Association for Fire Department equipment and a $2,500 grant from Taylor Family Farms Foundation for Ambulance Service equipment. City Administrator Tony Chladek updated on the Farmers Win cooperative site redevelopment feasibility study, preparing a UMN grant for potential entertainment/event space. The council also approved a $1,225 annual contract with ESRI for GIS services.

Robert F. Kennedy Jr. opposes using medications like Ozempic for obesity and diabetes, advocating for dietary and behavioral changes instead, despite Denmark's use of Ozempic and its sister drug Wegovy. Kennedy's anti-vaccine stance and misleading statements worry public health experts, who argue that medication should not be demonized and that lifestyle changes alone do not solve obesity.

46% of NF1 patients responded to mirdametinib, with 53 of 114 achieving ≥20% PN volume reduction. Responses included 24 adults and 29 children, with reductions up to 80%. Treatment was well-tolerated, with dermatitis acneiform and diarrhea as common TRAEs. FDA approval expected in early 2025.

Article lists affiliations and funding sources for researchers in nephrology and critical care from various institutions, including University of Minnesota, University of Chicago, King’s College London, and University of Washington. Funding sources include Novartis, Bioporto, Biomerieux, NIH, and others.

Mirdametinib, a MEK1/2 inhibitor, showed significant tumor volume reductions, pain, and QOL improvements in NF1-PN patients in the ReNeu trial, with 41% ORR in adults and 52% in children, highlighting its potential as a new treatment option.

HSG Conference's final day focused on HD research basics, treatment approaches, and community involvement, highlighting advancements in huntingtin-lowering drugs and biomarkers like NfL, and emphasizing the importance of participation in observational studies and community support.